Pyxis Oncology, Inc. (PYXS) News
Track canonical SquawkNews coverage tagged to PYXS, Pyxis Oncology, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 28 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Pyxis Oncology price target raised to $8.00 from $6.00 by Wedbush
EQUITY | Sep 10, 2026, 01:09 PM UTC
L
Pyxis Oncology price target raised to $8.00 from $7.00 by HC Wainwright
HC Wainwright & Co. raised its price target on Pyxis Oncology to $8.00 from $7.00. The firm maintained a Buy rating, per the TradingView News item relayed by Benzinga.
EQUITY | Sep 10, 2026, 10:40 AM UTC
L
PYXS kept at Overweight by Wells Fargo
Wells Fargo maintained an Overweight rating on Pyxis Oncology (PYXS).
EQUITY | Sep 09, 2026, 03:45 PM UTC
L
PYXS: WFC raises price target to $19
PYXS price target raised to $19 by WFC, according to TradeXchange Newsdesk.
EQUITY | Sep 09, 2026, 02:57 PM UTC
M
PYXS MICVO shows 36% confirmed response in advanced head and neck cancer
MICVO showed a 36% confirmed response rate and 94% disease control rate in heavily pretreated head and neck cancer patients. Median PFS was 6.2 months and 12-month OS probability 79%, with manageable safety.
CENTRAL_BANK | Sep 09, 2026, 02:06 PM UTC
M
PYXS MICVO shows strong efficacy and safety in advanced head/neck cancer
MICVO demonstrated a 36% response rate and 94% disease control in heavily pretreated head and neck cancer patients, with rapid, deep, durable responses and a manageable safety profile. Consistent subgroup efficacy suppor
CENTRAL_BANK | Sep 09, 2026, 01:03 PM UTC
L
Pyxis slides after new Phase 1 trial data for lead MICVO option
Pyxis Oncology (PYXS) fell more than 13% in premarket trading after Phase 1 early-stage data for micvotabart pelidotin (MICVO) as a late-line option for certain head and neck carcinoma.
EQUITY | Sep 09, 2026, 12:51 PM UTC
M
Pyxis Oncology reports 36% cORR, 6.2-month mPFS, 79% 12-month OS probability
Pyxis Oncology reported a 36% confirmed objective response rate and 6.2-month median PFS for MICVO in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
CENTRAL_BANK | Sep 09, 2026, 11:43 AM UTC
M
PYXS MICVO posts 36% response rate and 6.2-month PFS in HNSCC
MICVO showed a 36% response rate and 6.2-month median PFS in 2L+ R/M HNSCC. Safety was manageable, with late-onset, reversible neuropathy. Phase 3 initiation is planned for mid-2027.
CENTRAL_BANK | Sep 09, 2026, 11:37 AM UTC
M
PYXS data shows 36% response and 94% disease control
PYXS reports MICVO results in heavily pretreated recurrent/metastatic head and neck cancer: 36% objective response rate, 94% disease control rate, and 6.2-month median progression-free survival. No new safety signals; do
CENTRAL_BANK | Sep 09, 2026, 11:03 AM UTC
M
Pyxis Oncology reports positive updated MICVO Phase 1 monotherapy data
Pyxis Oncology said its MICVO Phase 1 monotherapy study showed 36% cORR and 94% DCR, with rapid and deep responses and activity across HPV status and prior-treatment subgroups.
CENTRAL_BANK | Sep 09, 2026, 11:03 AM UTC
M
Pyxis Oncology reports positive updated Phase 1 MICVO monotherapy data
Pyxis Oncology says updated Phase 1 monotherapy study data for micvotabart pelidotin (MICVO) is positive in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
EQUITY | Sep 09, 2026, 11:00 AM UTC
L
PYXS to host webcast with updated Phase 1 MICVO data
Pyxis Oncology will host a webcast to present updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
EQUITY | Sep 08, 2026, 08:01 PM UTC
L
Pyxis Oncology makes Thomas Civik permanent CEO
Pyxis Oncology appointed interim CEO Thomas Civik to a permanent CEO role. The clinical-stage company also named Civik board chair; he has served as interim CEO since February and on the board since 2021.
EQUITY | Sep 08, 2026, 12:04 PM UTC
L
Pyxis Oncology names Thomas Civik CEO, chairman
Pyxis Oncology appointed Thomas Civik as permanent chief executive officer and chairman, effective September 4, 2026. John Flavin becomes lead independent director and compensation committee chair.
REGULATION | Sep 08, 2026, 11:44 AM UTC
L
Pyxis Oncology appoints Thomas Civik CEO and board chairman
Pyxis Oncology appointed Thomas Civik chief executive officer and chairman of the board.
EQUITY | Sep 08, 2026, 11:30 AM UTC
M
BP appoints Ian Tyler as chair; Halma deal targets Pyxis
BP appointed Ian Tyler as chairman, effective immediately. Separately, Halma agreed to acquire Pyxis, according to the stocks-to-watch note.
MNA | Sep 02, 2026, 06:46 AM UTC
M
Halma to acquire Pyxis, water-quality monitoring technology provider
Halma plc announced it will acquire Pyxis, a specialist provider of water quality monitoring and analysis technology.
MNA | Sep 02, 2026, 06:03 AM UTC
L
Pyxis Oncology CEO to participate in upcoming investor conferences
Pyxis Oncology said Tom Civik, interim CEO and director, will participate in upcoming investor conferences, including a fireside discussion.
EQUITY | Sep 01, 2026, 11:37 AM UTC
L
PYXS - Pyxis Oncology to Participate in Upcoming Investor Conferences
PYXS - Pyxis Oncology to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 11:30 AM UTC
L
RCL completes $1.25 billion senior unsecured notes offering
RCL completes its offering of $1.25 billion senior unsecured notes due 2034; the wire also lists secondary-stock offering and registration items for AVAH, BKV, NCEL and PYXS.
RATES | Aug 21, 2026, 10:59 AM UTC
L
Pyxis Oncology files S-3 for selling stockholders
Pyxis Oncology files a Form S-3 covering up to 39,200,306 shares of common stock offered by selling stockholders.
REGULATION | Aug 20, 2026, 08:29 PM UTC
L
Pyxis Oncology reports Q2 2026 results, advances MICVO milestones
Pyxis Oncology (PYXS) reports second-quarter 2026 financial results and says it is advancing MICVO toward key 2026 clinical milestones, according to the company release.
EARNINGS | Aug 13, 2026, 11:00 AM UTC
H
Stocks Rise After Upgrades, Initiations
Select stocks gain after upgrades and initiations
EQUITY | Aug 03, 2026, 11:52 AM UTC
H
Wells Fargo Initiates PYXS Overweight
Wells Fargo initiates PYXS overweight with $12 target
EQUITY | Aug 03, 2026, 11:48 AM UTC
M
Analysts Initiate Coverage
Multiple stocks receive new analyst coverage
EQUITY | Aug 03, 2026, 10:58 AM UTC
L
Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ: PYXS ) with a Outperform and lowers the price target from $9 to $7.
EQUITY | Jul 02, 2026, 12:34 PM UTC
H
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers INVO Fertility (NASDAQ: IVF ) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings came out 4 days ag
EARNINGS | Jun 26, 2026, 05:05 PM UTC